secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001193125-23-045663
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q4 net loss $0.92/sh; cash $466M; board adds McCormick; acoramidis data mid-2023
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $137.6M in Q4 ($0.92/sh); full year $481.2M ($3.26/sh).
- Cash, equivalents, marketable securities $466.2M at Dec 31, 2022, down from $787.7M; provides runway into 2024.
- Phase 3 ATTRibute-CM trial of acoramidis for ATTR-CM topline data expected mid-2023.
- Phase 2 PROPEL 2 infigratinib cohort 5 data expected March 2023; Phase 3 initiation planned 2023.
- Board changes: Richard Scheller and Brenton Saunders resigned; Frank McCormick appointed to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/d472572d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-045663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer